Celsion's Ovarian Cancer Immunotherapy Shows 38% Improvement In R0 Resection Rates Versus Control Arm

Celsion Corporation (NASDAQ: CLSN) reports interim observations and provides an update on its Phase 1/2 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 3/4 ovarian cancer.
GEN-1 is a DNA-mediated interleukin-12 (IL-12) immunotherapy.
The OVATION 2 study combines GEN-1 with standard-of-care neoadjuvant chemotherapy. NACT is designed to shrink cancer as much as possible for optimal surgical removal after three chemotherapy cycles.
Celsion has enrolled 34 of the anticipated 110 patients, from which 20 are in the treatment arm and 14 are in control.
12 of 15 patients treated with GEN-1 had an R0 resection, which indicates a microscopically margin-negative complete resection in which no gross or microscopic tumor remains in the tumor bed.
7 of 12 patients in the control arm had an R0 resection.
Enrollment in the study to complete during the second half of 2021.
Earlier this week, CLSN stock rallied after GEN-1 received Fast Track Designation for advanced ovarian cancer.
Price Action: CLSN at up 1.23% at $2.33 in market trading hours on the last check Thursday.